JP Morgan Chase’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
Other funds holding TCRT
JP Morgan Chase's TCRT Position: Q3 2026 in Review
JP Morgan Chase opened a new position in Alaunos Therapeutics (TCRT) in Q3 2026: 7 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #8081 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in TCRT as recently as Q2 2025.
JP Morgan Chase first reported a position in TCRT in Q2 2013 and has held it in 37 quarters since. The position peaked at $18.9M in Q1 2021. 31 funds tracked by Wall St. Rank hold TCRT as of Q3 2026.
- JP Morgan Chase held 7 shares of Alaunos Therapeutics worth $7 as of Q3 2026.
- Alaunos Therapeutics was a new JP Morgan Chase position in Q3 2026.
- Alaunos Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8081 holding.
- JP Morgan Chase first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 37 quarters since.
- JP Morgan Chase's Alaunos Therapeutics position peaked at $18.9M in Q1 2021.
- 31 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.